
Axon Neuroscience to Introduce World's First Crowdfunded Vaccine against Covid-19
By
CIO Applications Europe | Monday, September 21, 2020

Axon Neuroscience is an industry-leading, clinical-stage biotech company at the forefront of peptide-based vaccines against fatal human diseases.
FREMONT, CA: Axon Neuroscience, a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1.
Axon's scientists identified the weakest points of the SARS-CoV-2 virus and used them to design the vaccine. ACvac1 induced extensive antibody production in vaccinated mice, effectively blocking the live virus from replicating and confirming the soundness of Axon's approach. The company plans to begin first-in-human trials as early as the fourth quarter of 2020.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Based on these encouraging vaccine efficacy results, Axon has decided to open the project to individuals and small investors who will be able to invest directly from the project's website.
Michal Fresser, Chief Executive Officer of Axon, said: "There is a global race for a vaccine. Many large corporations are under a lot of pressure to get to a vaccine fast, which often leads to shortcuts and compromises. As an independent biotech with proven clinical-stage vaccine technology, our utmost priority has always been focused on efficacy without compromising safety. Now, we want to give people the opportunity to join us and make their personal contribution to bringing the world a vaccine."
ACvac1 is a prophylactic vaccine against COVID-19 intended to protect healthy individuals from infection. The vaccine contains only critical elements of the virus Spike (S) protein capable of inducing desirable immune responses to prevent the virus from interacting with its target host cells, thus preventing it from replicating.
Axon's peptide-based approach is designed to prevent the unwanted serious side effects observed in the trials of novel nucleic acid or conventional vaccine candidates against SARS-CoV-2.
Norbert Zilka, Chief Science Officer, said: "Axon's vaccine approach against COVID-19 is highly differentiated from the other vaccine developers and has enormous potential despite coming later in the race. We unraveled the mechanism of how the virus protects itself from an immune response and where its vulnerable parts are located so that we can efficiently target them."
More in News
Weekly Brief
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from CIO Applications Europe
THANK YOU FOR SUBSCRIBING


